Quote this publication Share Print

ENANTONE

-
Opinions on drugs - Posted on Nov 10 2009

Reason for request

Inclusion on the list of medicines reimbursed by National Insurance and approved for use by hospitals in the extension of indication “treatment of locally advanced prostate cancer”.

-


Clinical Benefit

Substantial

The actual benefit of ENANTONE is substantial.


Clinical Added Value

no clinical added value

ENANTONE SR 3.75 mg and 11.25 mg, do not improve actual benefit (level V) compared to other GnRH analogues in the treatment of locally advanced prostate cancer.


Contact Us

Évaluation des médicaments
All our publications